¡Ya estamos en ! Descubre más
3.13 USD
-0.06
1.88%
Al cierre Actualizado 16 oct, 4:00 p.m. EDT
Antes de la apertura del mercado
Después del cierre del mercado
3.11
-0.02
0.64%
1 día
-1.88%
5 días
-9.54%
1 mes
-30.6%
3 meses
-44.8%
6 meses
-57.24%
En lo que va del año
-80.38%
1 año
-60.23%
5 años
-32.4%
10 años
-89.23%
 

Acerca de: WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Empleados: 317

Noticias

Positivo
Neutral
Negativo
Sentimiento 3 meses
Positivo 28.6%
Neutral 61.9%
Negativo 9.5%
Neutral
GlobeNewsWire
hace 3 días
Wave Life Sciences to Present at Chardan's 10th Annual Healthcare Conference
CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in the “RNA Medicines: Next-Generation RNA Therapeutics” panel at Chardan's 10th Annual Healthcare Conference in New York City on Tuesday, October 20, 2026 at 9:45 a.m. ET.
Wave Life Sciences to Present at Chardan's 10th Annual Healthcare Conference
Neutral
GlobeNewsWire
hace 15 días
Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD
Following meeting with FDA, Wave plans for a single, two-year registrational trial, with a one-year interim analysis for potential accelerated approval based on AATD biomarkers
Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD
Neutral
GlobeNewsWire
hace 16 días
Wave Life Sciences Announces GSK's Selection of siRNA program to Transition to GSK for Further Development
Candidate selected by GSK utilizes Wave's best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three additional collaboration programs advancing
Wave Life Sciences Announces GSK's Selection of siRNA program to Transition to GSK for Further Development
Positivo
Zacks Investment Research
hace 18 días
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
Neutral
GlobeNewsWire
hace 23 días
Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity
WVE-007 induces fat loss without muscle loss, with clinical data supporting 1-2x per year dosing; preclinical data demonstrate Wave's INHBE GalNAc-siRNA in combination with GLP-1 doubled weight loss compared with GLP-1 alone
Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity
Neutral
GlobeNewsWire
hace 24 días
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer
Dr. Vnuk brings substantial business and corporate development leadership experience from Sanofi, Blackstone, and Pfizer CAMBRIDGE, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer
Positivo
Market Watch
hace 25 días
These beaten-down stocks could bounce back in January, if history is any guide
Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year
These beaten-down stocks could bounce back in January, if history is any guide
Neutral
GlobeNewsWire
el mes pasado
Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.
Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference
Positivo
24/7 Wall Street
hace 2 meses
Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover
Wave Life Sciences (NASDAQ:WVE) trades at $5.24, a step above its 52-week low of $5.01 and far beneath the 52-week high of $21.73.
Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover
Neutral
Seeking Alpha
hace 2 meses
Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript
Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript
Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript
Gráficos de precios implementados con Lightweight Charts™